ANN ARBOR, Mich., March 17 /PRNewswire-USNewswire/ -- MichBio, the association for Michigan biosciences, will host Harry Stylli, Ph.D., president and CEO of San Diego, CA-based Sequenom, Inc. as the keynote speaker for its May 6 Annual Business Meeting at the Kensington Court Hotel in Ann Arbor. Sequenom has established a presence in Michigan with recent acquisitions of the Center for Molecular Medicine (CMM) in Grand Rapids and Ann Arbor-based Sensigen.
Dr. Harry Stylli has a track record of nearly two decades, demonstrating entrepreneurial leadership in the biotechnology and pharmaceutical industries, and has broad experience in successfully translating innovative technology into commercial opportunities. He was appointed president, CEO, and a board member of Sequenom, Inc. in 2005. Most recently, he served as president and CEO of Xencor, Inc., a privately held biotechnology company. Previously, Dr. Stylli was president and CEO of CovX Pharmaceuticals. Dr. Stylli co-founded Aurora Biosciences in 1995, and in 2001 he was key to the success of Aurora's acquisition by Vertex Pharmaceuticals. Following the merger, Dr. Stylli continued on with the company as president of Aurora Biosciences and Panvera. From 1987 to 1995, Dr. Stylli held various positions with GlaxoSmithKline. Dr. Stylli is a director of Molecular Insight Pharmaceuticals, Inc., and an advisor to Nanosyn. He has a B.S. degree from the University of East London, U.K., a Ph.D. from London University's Faculty of Medicine, and an M.B.A. from the U.K.'s Open University.
The MichBio Annual Business Meeting draws the industry's leaders and most influential bioscience professionals from across the state. It will be held at the Kensington Court Hotel in Ann Arbor, MI. Reception and networking begin at 5:00 p.m., followed by a dinner meeting at 6:30 p.m. and keynote address at 7:15 p.m. The cost before May 1 is $80 for members, $110 for non-members. After May 1
Copyright©2009 PR Newswire.
All rights reserved